Bio-Techne Corporation
NASDAQ:TECHBiotechnology
-$1.03 today
- Market cap
- $11.43B
- Beta
- 1.36
- P/E (TTM)
- 78.3
- EPS (TTM)
- $0.70
- Dividend yield
- 0.58%
Volume 2.63M
Average 2.66M
TECH Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Bio-Techne CorporationNASDAQ: TECH
Selling, General & Admin · Q1 FY2027 · quarter ended Sep 2026
Selling, general & admin grows in line with its trailing trend
Q1 FY2027 selling, general & admin of $133.68M rose 15.0% year over year, ahead of the +14.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 18.1% from the prior quarter. Over 3 fiscal years it compounded at +8.7% a year.
Context
- Selling, general & admin amounted to 37.2% of revenue in FY2026, up 3.2 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $424.57M (-6.2%) for the fiscal year ending Jun 2027, a slowdown from the +9.0% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $133.68M+18.1% QoQ
- Last fiscal yearJun 2026
- $452.42M+9.0% YoY
- LTMSep 2026
- $469.88M+14.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2026
- 452.42M USD
- Year-over-year change
- +9.0%
- 4-year CAGR
- +7.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 452.42M | +9.0% |
| FY2025 | 2025-06-30 | 415.1M | +5.5% |
| FY2024 | 2024-06-30 | 393.32M | +11.6% |
| FY2023 | 2023-06-30 | 352.44M | +4.0% |
| FY2022 | 2022-06-30 | 339M | — |
Selling, General & Admin vs competitors
How TECH compares with its peers on the latest reported figures
- TECH's LTM Sep 2026 selling, general & admin of $469.88M is the 8th highest of the 11 companies compared; the peer median is $895.19M.
- Its year-over-year change of +14.0% is the highest of 10, against a peer median of +3.0%.
- Selling, general & admin amounts to 38.3% of revenue for TECH, versus a peer median of 32.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $8.12B | +2.6% | +4.9% | 31.7% | |
| LTM Sep 2026 | $7.92B | -3.4% | -1.1% | 16.7% | |
| LTM Jul 2026 | $1.84B | +9.9% | +1.4% | 25.0% | |
| LTM Jun 2026 | $970.7M | +4.1% | +15.9% | 27.7% | |
| LTM Jul 2026 | $942.58M | +3.4% | +7.6% | 32.4% | |
| LTM Jun 2026 | $847.8M | +3.3% | -0.3% | 32.7% | |
| LTM Jun 2026 | $586.14M | +3.0% | -1.1% | 27.9% | |
| LTM Sep 2026 | $469.88M | +14.0% | +8.7% | 38.3% | |
| LTM Sep 2026 | $297.71M | -10.7% | +2.0% | 48.1% | |
| LTM Mar 2026 | $40.57M | -24.5% | -6.8% | 269.8% | |
ALMRAlamar Biosciences, Inc. | FY2025 | $35.57M | — | — | 47.9% |
| Peer median (excluding TECH) | $895.19M | +3.0% | +1.4% | 32.0% | |
Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 1.11B | 1.14B | 1.16B | 1.22B | 1.22B |
| Cost of Revenue | 349.1M | 366.89M | 389.34M | 429.36M | 415.97M |
| Gross Profit | 756.5M | 769.82M | 769.73M | 790.27M | 799.07M |
| Gross Margin | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
| Research & Development | 87.14M | 92.49M | 96.66M | 99.5M | 94.77M |
| Selling, General & Admin | 339M | 352.44M | 393.32M | 415.1M | 452.42M |
| Operating Expenses | 459.91M | 470.87M | 563.04M | 688.02M | 547.18M |
| Depreciation & Amortization | 101.07M | 107.24M | 111.71M | 109.9M | 97.36M |
| EBITDA | 413.76M | 457.11M | 313.14M | 216.88M | 343.44M |
| EBITDA Margin | 37.4% | 40.2% | 27.0% | 17.8% | 28.3% |
| Operating Income | 296.59M | 298.94M | 206.69M | 102.26M | 251.89M |
| Operating Margin | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Interest Income | 794K | 3.41M | 3.32M | 3.89M | 0 |
| Interest Expense | 11.31M | 11.22M | 15.74M | 8.51M | 5.41M |
| Other Income / Expenses | 4.8M | 39.72M | (21M) | (3.79M) | (11.21M) |
| Income Before Tax | 301.39M | 338.66M | 185.69M | 98.46M | 240.68M |
| Pre-Tax Margin | 27.3% | 29.8% | 16.0% | 8.1% | 19.8% |
| Income Tax Expense | 38.29M | 53.22M | 17.58M | 25.06M | 58.82M |
| Net Income | 272.05M | 285.26M | 168.11M | 73.4M | 181.86M |
| Net Margin | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
| EPS (Basic) | 1.73 | 1.81 | 1.07 | 0.47 | 1.17 |
| EPS (Diluted) | 1.66 | 1.76 | 1.05 | 0.46 | 1.16 |
| Weighted Avg Shares | 156.88M | 157.18M | 157.71M | 157.52M | 155.96M |
| Weighted Avg Shares (Diluted) | 164.12M | 161.86M | 160.77M | 159.72M | 157.01M |
Bio-Techne Corporation
NASDAQ:TECH
Intrinsic Alpha fair value
Locked
Current Price
$72.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.